All Metrics
PODD Valuation Metrics
PODD Stock Price Metrics
PODD Dividend Metrics
PODD Growth Rate Metrics
PODD Discounted Cash Flow Metrics
| Fair Value Price | - |
| Margin of Safety | - |
PODD Revenue Metrics
PODD PE Ratio Metrics
| PE Ratio | 80.98 |
| PE Ratio Avg TTM | 62.36 |
| PE Ratio Avg 3Y | 1159.57 |
| Current VS TTM Avg | +29.87% |
| Current VS 3Y Avg | -93.02% |
| Current VS 5Y Avg | -93.95% |
PODD PS Ratio Metrics
| PS Ratio | 7.38 |
| PS Ratio Avg TTM | 8.11 |
| PS Ratio Avg 3Y | 10.20 |
| Current VS TTM Avg | -8.95% |
| Current VS 3Y Avg | -27.61% |
| Current VS 5Y Avg | -41.33% |
PODD PB Ratio Metrics
| PB Ratio | 13.20 |
| PB Ratio Avg TTM | 14.15 |
| PB Ratio Avg 3Y | 22.96 |
| Current VS TTM Avg | -6.71% |
| Current VS 3Y Avg | -42.50% |
| Current VS 5Y Avg | -47.77% |
PODD Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 52.94 |
| PFCF Ratio Avg TTM | 56.42 |
| PFCF Ratio Avg 3Y | 109.58 |
| Current VS TTM Avg | -6.17% |
| Current VS 3Y Avg | -51.69% |
| Current VS 5Y Avg | -51.69% |
PODD Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.69 |
| Debt/Equity Ratio Avg TTM | 0.93 |
| Debt/Equity Ratio Avg 3Y | 1.71 |
| Current VS TTM Avg | -25.81% |
| Current VS 3Y Avg | -59.71% |
| Current VS 5Y Avg | -62.16% |
PODD PEG Ratio Metrics
| PEG Ratio | 0.44 |
| PEG Ratio Avg TTM | 0.23 |
| PEG Ratio Avg 3Y | 2.94 |
| Current VS TTM Avg | +95.56% |
| Current VS 3Y Avg | -85.02% |
| Current VS 5Y Avg | -86.00% |
PODD FCF Yield
| FCF Yield | 1.89% |
| FCF Yield Avg TTM | 1.78% |
| FCF Yield Avg 3Y | 0.96% |
| Current VS TTM Avg | +6.18% |
| Current VS 3Y Avg | +97.39% |
| Current VS 5Y Avg | +399.56% |
PODD Earnings Yield
| Earnings Yield | 1.24% |
| Earnings Yield Avg TTM | 1.77% |
| Earnings Yield Avg 3Y | 1.23% |
| Current VS TTM Avg | -29.75% |
| Current VS 3Y Avg | +1.02% |
| Current VS 5Y Avg | +47.62% |
PODD EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 42.91 |
| Ev/Ebit Ratio Avg TTM | 51.83 |
| Ev/Ebit Ratio Avg 3Y | 185.19 |
| Current VS TTM Avg | -17.20% |
| Current VS 3Y Avg | -76.83% |
| Current VS 5Y Avg | -78.76% |
PODD EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 18.52 |
| Ev/Ebitda Ratio Avg TTM | 37.43 |
| Ev/Ebitda Ratio Avg 3Y | 48.84 |
| Current VS TTM Avg | -50.52% |
| Current VS 3Y Avg | -62.08% |
| Current VS 5Y Avg | -80.17% |
PODD EV/Assets Ratio Metrics
| Ev/Assets Ratio | 6.37 |
| Ev/Assets Ratio Avg TTM | 6.22 |
| Ev/Assets Ratio Avg 3Y | 7.01 |
| Current VS TTM Avg | +2.33% |
| Current VS 3Y Avg | -9.13% |
| Current VS 5Y Avg | -16.91% |
PODD EV/Sales Ratio Metrics
| Ev/Sales Ratio | 7.51 |
| Ev/Sales Ratio Avg TTM | 8.29 |
| Ev/Sales Ratio Avg 3Y | 10.56 |
| Current VS TTM Avg | -9.35% |
| Current VS 3Y Avg | -28.87% |
| Current VS 5Y Avg | -41.90% |
PODD Current Ratio Metrics
| Current Ratio | 2.78 |
| Current Ratio Avg TTM | 3.16 |
| Current Ratio Avg 3Y | 3.34 |
| Current VS TTM Avg | -12.03% |
| Current VS 3Y Avg | -16.70% |
| Current VS 5Y Avg | -33.44% |
PODD Quick Ratio Metrics
| Quick Ratio | 2.11 |
| Quick Ratio Avg TTM | 2.42 |
| Quick Ratio Avg 3Y | 2.51 |
| Current VS TTM Avg | -12.81% |
| Current VS 3Y Avg | -15.85% |
| Current VS 5Y Avg | -35.64% |
PODD ROIC Metrics
| ROIC | 13.62% |
| ROIC Avg 3Y | 8.97% |
| ROIC Avg 5Y | 7.27% |
| Current VS 3Y Avg | +51.84% |
| Current VS 5Y Avg | +87.43% |
| Current VS 10Y Avg | +537.80% |
PODD Return on Assets Metrics
| ROA | 7.75% |
| ROA Avg TTM | 10.65% |
| ROA Avg 3Y | 7.37% |
| Current VS TTM Avg | -27.23% |
| Current VS 3Y Avg | +5.19% |
| Current VS 5Y Avg | +51.71% |
PODD Return on Equity Metrics
| ROE | 16.31% |
| ROE Avg TTM | 25.41% |
| ROE Avg 3Y | 19.99% |
| Current VS TTM Avg | -35.83% |
| Current VS 3Y Avg | -18.41% |
| Current VS 5Y Avg | +16.35% |
PODD Net Profit Margin Metrics
| Net Profit Margin | 9.12% |
| Net Profit Margin Avg TTM | 14.66% |
| Net Profit Margin Avg 3Y | 10.46% |
| Current VS TTM Avg | -37.77% |
| Current VS 3Y Avg | -12.77% |
| Current VS 5Y Avg | +24.08% |
Last Updated: Friday, June 26, 2026
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy